• Zai Lab Ltd ZLAB.OQ reported a quarterly adjusted loss of 80 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of six analysts for the quarter was for a loss of 65 cents per share. Wall Street expected results to range from -74 cents to -48 cents per share.

• Revenue rose 64.8% to $108.51 million from a year ago; analysts expected $110.21 million.

• Zai Lab Ltd's reported EPS for the quarter was a loss of 80 cents​.

• The company reported a quarterly loss of $81.68 million.

• Zai Lab Ltd shares had risen by 33.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Zai Lab Ltd is $50.00

This summary was machine generated from LSEG data February 27 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)